SAMSUNG BIOLOGICS CO.,LTD.
207940KOSPIPharmaceuticals
SAMSUNG BIOLOGICS CO.,LTD. (207940, KOSPI) reported KRW 4,557bn revenue in 2025.
Broker research: target prices and ratings
16 reports from 9 firms between 2026-08-31 and 2026-10-22. Taking the latest stated target from each of 9 firms, target prices range from KRW 1,850,000 to KRW 2,000,000; the median is KRW 2,000,000.
The 10 most recent reports, newest first. Ratings are as each firm stated them, translated into English. "Not stated" means the report carried no value — it is not a zero.
| Date | Target price | Rating | Firm | Analyst |
|---|---|---|---|---|
| KRW 1,900,000 | Buy | iM Securities | Not stated | |
| KRW 2,000,000 | Buy | IBK Investment & Securities | Not stated | |
| KRW 2,000,000 | Buy | Kiwoom Securities | Not stated | |
| KRW 2,000,000 | Buy | Daishin Securities | Not stated | |
| KRW 2,000,000 | Buy | Yuanta Securities Korea | Not stated | |
| KRW 1,950,000 | Buy | Hana Securities | Not stated | |
| KRW 1,900,000 | Buy | Kyobo Securities | Not stated | |
| KRW 2,000,000 | Buy | IBK Investment & Securities | Not stated | |
| KRW 2,000,000 | Buy | Daishin Securities | Not stated | |
| KRW 2,000,000 | Buy | SK Securities | Not stated |
Report titles are not shown: the source lists them in Korean only, and we do not publish our own translation of another firm's headline.
This is a record of what brokers published, not investment advice. It is a sample of broker research — the reports our collection picked up, not every report written on this company — and the range and median describe that sample, not a market consensus. These are statistics, not a verdict.
Source: broker reports collected by SeoulMarkets from Naver Finance's research listing and from brokers' own websites, 2026-06-29 to 2026-10-28.
Compare target prices across Korean biotech and pharma stocks →
Reported financials
Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.
| Year | Revenue | Operating profit | Net profit | Assets | Equity | Basis |
|---|---|---|---|---|---|---|
| 2021 | 1,568 | 537 | 394 | 7,970 | 4,991 | Consolidated |
| 2022 | 3,001 | 984 | 798 | 16,582 | 8,984 | Consolidated |
| 2023 | 3,695 | 1,114 | 858 | 16,046 | 9,830 | Consolidated |
| 2024 | 4,547 | 1,320 | 1,083 | 17,336 | 10,905 | Consolidated |
| 2025 | 4,557 | 2,069 | 1,784 | 11,061 | 7,451 | Consolidated |
Ratios, year by year
Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.
| Year | Operating margin | Net margin | Equity / assets | Return on equity |
|---|---|---|---|---|
| 2021 | 34.3% | 25.1% | 62.6% | 7.9% |
| 2022 | 32.8% | 26.6% | 54.2% | 8.9% |
| 2023 | 30.1% | 23.2% | 61.3% | 8.7% |
| 2024 | 29% | 23.8% | 62.9% | 9.9% |
| 2025 | 45.4% | 39.2% | 67.4% | 23.9% |
Revenue moved 190.6% between 2021 and 2025.
Net profit was positive in the 5 most recent consecutive years on file — every year we hold. It also grew in every one of those years, which 40 of 2,049 companies managed. Counted from the 5 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.
These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.
Market size
| Market capitalisation | KRW 67,214bn |
|---|---|
| Close price | KRW 1,452,000 |
| Listed shares | 46,290,951 |
| Price as of | 20260909 |
Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.
When it was founded
The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.
| Incorporated |
|---|
Who runs it
Registered representative directors — in Korea this is the office a CEO holds. Filed with the Financial Supervisory Service (DART). A Korean company can register more than one, and the title beside each name is the rank they carry inside the company.
| Name | Title | Board seat | Years in post |
|---|---|---|---|
| Rim John Chongbo (존림) | President | Inside director | 7 years |
Some Roman spellings here are not ours — the company filed them itself, either beside the Korean name or in place of one. Those are the spellings the company uses.
Workforce — a side measure, not the main one
| Employees (2025) | 5,455 |
|---|---|
| Women | 2,429 (44.5%) |
| Average tenure | 4.9 years |
| Annual pay, men | KRW 121,000,000 |
| Annual pay, women | KRW 106,000,000 |
| Pay ratio, women to men | 87.6% |
Other companies in Pharmaceuticals
181 listed companies file under this classification. Showing 12.